Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology - - Two new clinical trials, REFRaME-P1, a registration-enabling trial ...

Technology analyst Beth Kindig believes Nvidia will be worth $10 trillion by 2030. These three time-tested dividend growth ...

QuickBooks Online won't be your cheapest choice for accounting software, but its features make it a good solution for just ...

Learn how to optimize your small business finances with Melissa Broughton. Discover practical strategies and tools to ...

In the oral presentation, the investigators reported ongoing improved survival compared to historical controls, with 3 out of ...

That lower expense ... a sound balance sheet. The business operates with a 150% lower-bound and a 200% upper-bound range. Talanx has made fair investments. Over the past 10 years, we think there have ...

Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -- Two new ...

study On track for one to two DC nominations in 2025 from wave 1 Ionis collaboration programs focusing on cardiometabolic ...

Research and Development (R&D) Expenses ... class oral small molecule; the ability of the Company to bring GSBR-1290 to patients rapidly; the potential applications of ANPA-0073; and the planned ...

Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...

--(BUSINESS WIRE)--Alto Neuroscience ... ALTO-300 (agomelatine): Enrollment on track in Phase 2b adjunctive MDD trial. ALTO-300, an oral, small molecule designed to act as a melatonin agonist and ...

NEXT shares a checklist to help small businesses navigate tax preparation, bookkeeping, financial analysis, business strategy ...